In short
Clinical trials are investigating SAR445399 in adults with moderate to severe hidradenitis suppurativa. These studies aim to evaluate efficacy and safety, including different doses, in people living with this long-term skin condition.
Key points
- SAR445399 is being studied in a Phase 2 clinical trial for adults with moderate to severe hidradenitis suppurativa. The study is authorised and plans to include 206 participants. Researchers want to see how well different doses of SAR445399 work and whether the treatment is safe. The trial focuses on efficacy, which means how well the treatment helps the condition. The available trial data describe one interventional study in this skin disease.
Trial overview
This article covers one interventional study of SAR445399 in adults with moderate to severe hidradenitis suppurativa. The study is listed as authorised and is a Phase 2 trial with a planned enrollment of 206 participants.
Condition and target population
The trial is studying hidradenitis suppurativa (HS), a long-term skin condition, in adults who have moderate to severe disease. This means the study is focused on people whose symptoms are not mild and who may need more active treatment research options.
Study design and phase
The available data describe SAR445399 as part of a Phase 2 study. Phase 2 trials are used to learn more about whether a treatment may work and to keep checking safety in a defined patient group.
The study summary says it is evaluating different doses of SAR445399. In simple terms, the researchers are comparing amounts of the study treatment to see how well they may help people with this condition.
What is being measured
The main goal of the study is to evaluate efficacy, which means how well the treatment works for the target condition. The trial also aims to assess safety, meaning whether the treatment can be used without causing unacceptable harm in the study setting.
Because the brief summary specifically mentions efficacy of different doses, the study is likely focused on whether one dose works better than another for people with hidradenitis suppurativa.
Who may join the study
The trial data state that the study is for adult participants with moderate to severe hidradenitis suppurativa. No other eligibility details are provided in the source data, so the full set of entry rules cannot be confirmed here.
Why this trial matters
Hidradenitis suppurativa can be difficult to manage when it is moderate to severe, so studies like this one are important for finding better treatment options. This trial may help show whether SAR445399 is worth studying further in this patient group.